-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Saturday, Arrowhead Presents Plozasiran Data At AHA 2026 Showing 78% Lower Acute Pancreatitis Event Rate Versus Placebo And Sustained Triglyceride Reductions, Plus ARO-DIMER-PA Lowering LDL Cholesterol And Triglycerides

Benzinga·11/09/2026 08:23:32
Listen to the news
  • Pooled SHASTA-3 and SHASTA-4 analysis showed plozasiran reduced acute pancreatitis event rates by 78% overall and 91% in sHTG patients with a recent history of acute pancreatitis versus placebo
  • PALISADE open-label extension showed sustained reductions in triglycerides and APOC3 with plozasiran through up to 36 months of treatment in patients with FCS
  • Single doses of investigational dual-functional ARO-DIMER-PA produced mean LDL-C reductions of up to 65% and median triglyceride reductions of up to 78% from baseline